CA2256013A1 - Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic - Google Patents

Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Info

Publication number
CA2256013A1
CA2256013A1 CA002256013A CA2256013A CA2256013A1 CA 2256013 A1 CA2256013 A1 CA 2256013A1 CA 002256013 A CA002256013 A CA 002256013A CA 2256013 A CA2256013 A CA 2256013A CA 2256013 A1 CA2256013 A1 CA 2256013A1
Authority
CA
Canada
Prior art keywords
carboxamide
triazole
antiepileptic
difluorobenzyl
crystal modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002256013A
Other languages
French (fr)
Other versions
CA2256013C (en
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2256013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2256013A1 publication Critical patent/CA2256013A1/en
Application granted granted Critical
Publication of CA2256013C publication Critical patent/CA2256013C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

The invention relates to the novel modification A or A' of the compound 1-(2, 6-difluoroben-zyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy, and pharmaceutical preparations comprising this crystal modification.
CA002256013A 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic Expired - Lifetime CA2256013C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
CH1404/97 1997-06-10
PCT/EP1998/003427 WO1998056772A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Publications (2)

Publication Number Publication Date
CA2256013A1 true CA2256013A1 (en) 1998-12-17
CA2256013C CA2256013C (en) 2007-10-16

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2614926A Expired - Lifetime CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA002256013A Expired - Lifetime CA2256013C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA002256015A Expired - Lifetime CA2256015C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2614926A Expired - Lifetime CA2614926C (en) 1997-06-10 1998-06-08 Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002256015A Expired - Lifetime CA2256015C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Country Status (37)

Country Link
US (6) US6740669B1 (en)
EP (2) EP0994863B1 (en)
JP (2) JP3672575B2 (en)
KR (2) KR100409168B1 (en)
CN (3) CN1298708C (en)
AR (4) AR012945A1 (en)
AT (2) ATE232852T1 (en)
AU (2) AU725517B2 (en)
BR (2) BR9804946A (en)
CA (3) CA2614926C (en)
CO (2) CO4940448A1 (en)
CY (1) CY2007014I2 (en)
CZ (2) CZ292481B6 (en)
DE (3) DE69811500T2 (en)
DK (2) DK0994863T3 (en)
ES (2) ES2192779T3 (en)
FR (1) FR07C0037I2 (en)
HK (3) HK1028241A1 (en)
HU (2) HU225153B1 (en)
ID (2) ID21014A (en)
IL (2) IL125733A (en)
LU (1) LU91345I2 (en)
MY (2) MY120156A (en)
NL (1) NL300284I2 (en)
NO (2) NO329314B1 (en)
NZ (2) NZ331370A (en)
PE (2) PE79799A1 (en)
PL (2) PL191943B1 (en)
PT (1) PT994864E (en)
RU (2) RU2198167C2 (en)
SI (2) SI0994863T1 (en)
SK (2) SK283734B6 (en)
TR (2) TR199801631T1 (en)
TW (2) TW526195B (en)
UY (1) UY25844A1 (en)
WO (2) WO1998056773A1 (en)
ZA (2) ZA984967B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
CA2736703A1 (en) 2008-10-13 2010-04-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (en) * 2008-12-30 2012-01-04 北京本草天源药物研究院 Medicine crystal, preparation method and purpose thereof
IT1395736B1 (en) * 2009-08-04 2012-10-19 Dipharma Francis Srl CRYSTALLINE FORMS OF RUFINAMIDE
RU2594155C2 (en) * 2009-09-04 2016-08-10 Тэктикал Терапеутикс, Инк Novel compositions and methods of producing 5-amino- or substituted amino-1,2,3-triazoles and triazole-orotate compositions
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
ITMI20110718A1 (en) * 2011-04-29 2012-10-30 Dipharma Francis Srl PROCEDURE FOR PURIFICATION OF RUFINAMIDE
WO2014013511A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A (en) 1982-12-23 1984-06-24 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (en) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd Method for depositing crystal of compound having plural crystal forms
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
EP0556393B1 (en) 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
JP2753911B2 (en) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same
DE4217952A1 (en) 1992-05-30 1993-12-02 Basf Ag Quinoxaline-2,3 (1H, 4H) diones
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DK0812320T3 (en) 1995-02-22 2003-04-14 Aventis Pharma Ltd Amorphous pyrethanide, polymorphic forms thereof, process for their preparation and their use
EP0918758B1 (en) * 1996-07-11 2002-05-02 Novartis AG Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use

Also Published As

Publication number Publication date
PE79799A1 (en) 1999-09-03
AU8437198A (en) 1998-12-30
US20030125568A1 (en) 2003-07-03
EP0994864A1 (en) 2000-04-26
JP2000516258A (en) 2000-12-05
DE69813560D1 (en) 2003-05-22
RU2194041C2 (en) 2002-12-10
PL330798A1 (en) 1999-06-07
SK109398A3 (en) 1998-12-02
US20060116520A1 (en) 2006-06-01
WO1998056773A1 (en) 1998-12-17
AR012945A1 (en) 2000-11-22
KR100409168B1 (en) 2004-01-31
UY25844A1 (en) 2001-08-27
SK109498A3 (en) 1998-12-02
NZ331371A (en) 2000-08-25
TW403740B (en) 2000-09-01
WO1998056772A1 (en) 1998-12-17
HU226107B1 (en) 2008-04-28
DE69811500T2 (en) 2004-04-01
DK0994863T3 (en) 2003-05-26
TW526195B (en) 2003-04-01
HU225153B1 (en) 2006-07-28
AR061004A2 (en) 2008-07-30
ES2192779T3 (en) 2003-10-16
AR012946A1 (en) 2000-11-22
ZA984967B (en) 1999-01-11
CA2614926C (en) 2010-02-09
ATE232852T1 (en) 2003-03-15
KR19990087835A (en) 1999-12-27
NL300284I1 (en) 2007-10-01
NO983667D0 (en) 1998-08-11
US8076362B2 (en) 2011-12-13
DK0994864T3 (en) 2003-07-21
IL125732A0 (en) 1999-04-11
CY2007014I1 (en) 2009-11-04
US20100310655A1 (en) 2010-12-09
KR100425656B1 (en) 2004-05-17
HUP0000798A3 (en) 2000-10-30
CZ292481B6 (en) 2003-09-17
NZ331370A (en) 2000-08-25
CY2007014I2 (en) 2009-11-04
SI0994864T1 (en) 2003-10-31
IL125733A0 (en) 1999-04-11
CA2614926A1 (en) 1998-12-17
DE69811500D1 (en) 2003-03-27
SI0994863T1 (en) 2003-08-31
NO329314B1 (en) 2010-09-27
CZ253398A3 (en) 1999-04-14
LU91345I9 (en) 2018-12-31
FR07C0037I1 (en) 2007-08-17
PL330764A1 (en) 1999-05-24
SK283734B6 (en) 2003-12-02
EP0994864B1 (en) 2003-04-16
KR19990087836A (en) 1999-12-27
CA2256013C (en) 2007-10-16
US20040167186A1 (en) 2004-08-26
PT994864E (en) 2003-07-31
US6455556B2 (en) 2002-09-24
JP3672574B2 (en) 2005-07-20
BR9804947A (en) 1999-08-24
NO983666D0 (en) 1998-08-11
TR199801631T1 (en) 1999-06-21
AU8437298A (en) 1998-12-30
NL300284I2 (en) 2007-11-01
LU91345I2 (en) 2007-09-04
CZ253498A3 (en) 1999-04-14
ID21014A (en) 1999-04-08
AU725528B2 (en) 2000-10-12
NO329315B1 (en) 2010-09-27
CZ292260B6 (en) 2003-08-13
DE122007000051I2 (en) 2009-02-19
ES2197485T3 (en) 2004-01-01
HK1028031A1 (en) 2001-02-02
AU725517B2 (en) 2000-10-12
US20010037029A1 (en) 2001-11-01
NO983667L (en) 1998-12-17
MY120156A (en) 2005-09-30
BR9804946A (en) 1999-08-24
IL125733A (en) 2002-12-01
JP2000516259A (en) 2000-12-05
US7750028B2 (en) 2010-07-06
JP3672575B2 (en) 2005-07-20
HK1028241A1 (en) 2001-02-09
PL192114B1 (en) 2006-08-31
IL125732A (en) 2002-12-01
ID27660A (en) 2001-04-19
ATE237599T1 (en) 2003-05-15
CA2256015A1 (en) 1998-12-17
CA2256015C (en) 2008-06-03
AR061005A2 (en) 2008-07-30
HUP0002113A3 (en) 2002-09-30
CN1217716A (en) 1999-05-26
DE69813560T2 (en) 2004-02-05
CN1572789A (en) 2005-02-02
CN1132820C (en) 2003-12-31
HUP0000798A2 (en) 2000-10-30
RU2198167C2 (en) 2003-02-10
DE122007000051I1 (en) 2007-11-08
TR199801630T1 (en) 1999-06-21
PL191943B1 (en) 2006-07-31
CO4940452A1 (en) 2000-07-24
FR07C0037I2 (en) 2008-05-16
MY125854A (en) 2006-08-30
PE80999A1 (en) 1999-09-06
EP0994863A1 (en) 2000-04-26
CN1159300C (en) 2004-07-28
NO983666L (en) 1998-12-17
US6740669B1 (en) 2004-05-25
HK1028242A1 (en) 2001-02-09
CN1298708C (en) 2007-02-07
CO4940448A1 (en) 2000-07-24
SK283685B6 (en) 2003-12-02
EP0994863B1 (en) 2003-02-19
HUP0002113A2 (en) 2001-02-28
ZA984966B (en) 1999-01-11
CN1259127A (en) 2000-07-05

Similar Documents

Publication Publication Date Title
CA2256013A1 (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
CA2276455A1 (en) Phthalazinones
CA2210258A1 (en) Substituted oxazolidine calpain and/or cathepsin b inhibitors
AU6836200A (en) Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
CA2371012A1 (en) 4-(1h-pyrrol-1-yl) imidazoles
IL127597A0 (en) Iso-taxol analogs
CA2245267A1 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
CA2270177A1 (en) Transdermal administration of ment
CA2219656A1 (en) Antibacterial cephalosporins
CA2152771A1 (en) 7-o-ethers of taxane derivatives
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
CA2038984A1 (en) Hydroxymethyl-indolizidines and quinolizidines
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
CA2225156A1 (en) Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
WO2001005228A3 (en) Fungicidal combinations of active substances
AU7161794A (en) Quinoline compounds
CA2206172A1 (en) New derivatives of 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
MY116562A (en) Fungicidal active compound combinations
CA2168517A1 (en) Substituted thiophenylsulfonylureas and -thioureas processes for their preparation, their use as a medicament or diagnostic, and medicament containing them
AU1067795A (en) Use of lithium compounds in the treatment and prevention of alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180608